Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | DHPS | P49366 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27702693 | 0.89 | LIPG (0.50) | LIPGKMT2AHDAC6 | |
| SCHEMBL27723158 | 0.87 | LIPG (0.60) | LIPGCYP2C9CYP2C19KMT2A | |
| SCHEMBL6078714 | 0.86 | LIPG (0.43) | LIPGCASP3KMT2AHDAC6DHPS | |
| SCHEMBL6077310 | 0.84 | LIPG (0.56) | LIPGPARP1KMT2AL3MBTL1HDAC6 | |
| SCHEMBL27723159 | 0.84 | CYP1A2 (0.53) | LIPGPOLBCYP2D6CYP2C19 | |
| SCHEMBL6078108 | 0.83 | LIPG (0.62) | LIPG | |
| SCHEMBL27840855 | 0.83 | PARP1 (0.50) | LIPGCASP3PARP1POLBCYP2D6 | |
| SCHEMBL6079147 | 0.82 | LIPG (0.54) | LIPGPARP1HDAC6 | |
| SCHEMBL4755307 | 0.82 | CASP3 (0.70) | LIPGCASP3KMT2A | |
| SCHEMBL27723156 | 0.81 | ATM (0.48) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101190894-A | Fatty acid synthetic enzyme inhibitor and medical preparation use thereof | POISON MED INST PLA MED ACAD (CN) | 2008-06-04 | — | — | CN | disclosed |
| EP-1044204-B1 | PROCESS FOR THE PREPARATION OF ALPHA-OXOLACTAMS | RES CORP TECHNOLOGIES INC (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6255479-B1 | REACTING AN ALPHA-DIAZOLACTAM WITH AN EPOXIDE, IN THE PRESENCE OF A TRANSITION METAL CATALYST (OF RHODIUM, COPPER, OR RHENIUM), YIELDS ALPHA-OXOLACTAM | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2001-07-03 | — | — | US | disclosed |
| EP-1044204-A1 | PROCESS FOR THE PREPARATION OF ALPHA-OXOLACTAMS | Research Corporation Technologies, Inc (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999033837-A1 | PROCESS FOR THE PREPARATION OF α-OXOLACTAMS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-07-08 | — | — | WO | disclosed |